Elutia Framtida tillväxt
Future kriterier kontrolleras 0/6
Elutia s intäkter förväntas minska med 0.4% per år medan dess årliga intäkter förväntas växa med 3.2% per år. EPS förväntas tillväxt med 0.2% per år.
Viktig information
-0.4%
Tillväxttakt i vinsten
0.25%
Tillväxttakt för EPS
| Biotechs vinsttillväxt | 25.5% |
| Intäkternas tillväxttakt | 3.2% |
| Framtida avkastning på eget kapital | n/a |
| Bevakning av analytiker | Low |
| Senast uppdaterad | 15 May 2026 |
Senaste uppdateringarna om framtida tillväxt
Recent updates
Uppdatering av berättelse • Mar 04
ELUT: Listing Compliance Recovery Will Support Future Reconstructive Portfolio Upside
Analysts have adjusted their price target on Elutia to reflect updated views on profitability, with a lower assumed profit margin and a higher future P/E estimate shaping the new valuation in dollar terms. What's in the News Elutia received a written notice from Nasdaq on December 23, 2025 stating that it is not in compliance with the minimum market value of listed securities requirement of $35 million under Nasdaq Listing Rule 5550(b)(2) (Key Developments).Uppdatering av berättelse • Feb 18
ELUT: Listing Compliance Progress Will Support Future Reconstructive Portfolio Upside
Analysts have revised their price target on Elutia to $3.50, maintaining their fair value estimate while updating assumptions on the discount rate, revenue growth, profit margin, and future P/E to align with their current assessment of the company’s risk and earnings profile. What's in the News Elutia received a written notice from Nasdaq stating that it is not in compliance with the minimum market value of listed securities requirement of $35m under Listing Rule 5550(b)(2).Analysartikel • Feb 15
Elutia Inc. (NASDAQ:ELUT) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Elutia Inc. ( NASDAQ:ELUT ) shares have continued their recent momentum with a 28% gain in the last month alone. But...
Uppdatering av berättelse • Feb 04
ELUT: Future Nasdaq Compliance Resolution Will Support Bullish Repricing Potential
Analysts have maintained their price target on Elutia at US$5.00, citing a slightly lower discount rate, a modest change in expected revenue contraction, and a small adjustment to future P/E assumptions, along with a slightly higher projected profit margin. What's in the News On December 23, 2025, Elutia received a Nasdaq notice that its market value of listed securities had been below the US$35 million minimum for 30 consecutive business days, and that it also did not meet certain shareholder equity and net income standards required for continued listing on The Nasdaq Capital Market (Nasdaq notice).Uppdatering av berättelse • Jan 21
ELUT: Future Nasdaq Compliance Progress Will Drive Bullish Repricing Potential
Narrative Update on Elutia Analysts have maintained their price target for Elutia at US$5.00, citing slightly lower assumed revenue growth, a modestly higher profit margin outlook, and a small adjustment to the discount rate and future P/E assumptions as key drivers behind the updated view. What's in the News On December 23, 2025, Nasdaq notified Elutia that its market value of listed securities had been below the US$35 million minimum required under Listing Rule 5550(b)(2) for 30 consecutive business days, and that the company also did not meet related shareholder equity or net income standards (Nasdaq notice).Uppdatering av berättelse • Jan 07
ELUT: Future Compliance Recovery Will Support Bullish Repricing Potential
Analysts have reduced their price target on Elutia by US$1.00. They cite a higher discount rate, a projected revenue decline of 7.18%, and a much higher future P/E estimate, partly offset by slightly stronger expected profit margins.Uppdatering av berättelse • Dec 16
ELUT: Future Listing Compliance Efforts Will Support Reconstructive Portfolio Expansion
Narrative Update on Elutia Analysts have modestly adjusted their price target on Elutia upward to reflect a slightly more constructive long term earnings and valuation outlook, nudging the fair value estimate higher by approximately $0.00 per share as updated model inputs had only a de minimis impact on the overall target. What's in the News Elutia received a notice from Nasdaq that its Class A common stock has traded below the $1.00 per share minimum bid price for 30 consecutive business days, triggering a formal deficiency notification and potential delisting process (Nasdaq listing notice).Analysartikel • Dec 06
Lacklustre Performance Is Driving Elutia Inc.'s (NASDAQ:ELUT) 28% Price Drop
To the annoyance of some shareholders, Elutia Inc. ( NASDAQ:ELUT ) shares are down a considerable 28% in the last...Uppdatering av berättelse • Dec 02
ELUT: Recent Business Sale Will Fund Breast Reconstruction Growth Ahead
Analysts have lowered Elutia's target price from $8.00 to $6.00, citing a smaller-than-expected sale price for the BioEnvelope business. However, they note that the deal removes significant overhangs and provides full funding for Elutia's breast reconstruction segment.Uppdatering av berättelse • Nov 17
ELUT: Recent Business Sale Will Unlock Breast Reconstruction Focus
Narrative Update on Elutia Elutia's analyst price target has been reduced from $8 to $6 following analysts’ assessment that, although the sale of the BioEnvelope business provides significant funding, the lower-than-expected acquisition price tempers near-term expectations for the company's growth. Analyst Commentary Analysts have weighed in on the implications of Elutia's recent business developments, offering a nuanced perspective on the company's outlook.Uppdatering av berättelse • Nov 01
ELUT: Breast Reconstruction Funding Will Drive Long-Term Shareholder Value
Elutia's analyst price target has decreased from $8 to $6, as analysts factor in the sale of its BioEnvelope business. While this sale is seen as bittersweet, it helps eliminate notable uncertainties and secures funding for the company's breast reconstruction segment.Uppdatering av berättelse • Oct 17
Aging Demographics And Chronic Conditions Will Spur Healing Advances
Analysts have reduced their price target for Elutia from $8 to $6 per share, citing both the lower-than-expected sale price of its BioEnvelope business and the improved funding outlook for its core breast reconstruction segment. Analyst Commentary Recent analyst reports provide a nuanced view of Elutia's prospects following the BioEnvelope business sale.Analysartikel • Oct 13
The Market Doesn't Like What It Sees From Elutia Inc.'s (NASDAQ:ELUT) Revenues Yet As Shares Tumble 30%
To the annoyance of some shareholders, Elutia Inc. ( NASDAQ:ELUT ) shares are down a considerable 30% in the last...Uppdatering av berättelse • Oct 03
Aging Demographics And Chronic Conditions Will Spur Healing Advances
Analysts have reduced their price target for Elutia, with recent adjustments citing a new range from $8 to $5 per share. This reflects cautious optimism about the firm's strategic divestiture and future growth prospects, despite near-term revenue challenges.Uppdatering av berättelse • Sep 10
Aging Demographics And Chronic Conditions Will Spur Healing Advances
Elutia's fair value estimate has been revised downward due to sharply reduced revenue growth forecasts and a significantly higher future P/E multiple, resulting in the consensus price target dropping from $6.50 to $5.50. What's in the News Elutia was selected to exhibit its EluPro Antibiotic-Eluting BioEnvelope at the Vizient Innovative Technology Exchange, providing exposure to hospital supply chain and clinical leaders.Analysartikel • Aug 29
Elutia Inc.'s (NASDAQ:ELUT) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Elutia Inc. ( NASDAQ:ELUT ) shareholders have had their patience rewarded with a 27% share price jump in the last...Analysartikel • Aug 19
US$6.50: That's What Analysts Think Elutia Inc. (NASDAQ:ELUT) Is Worth After Its Latest Results
NasdaqCM:ELUT 1 Year Share Price vs Fair Value Explore Elutia's Fair Values from the Community and select yours Elutia...Uppdatering av berättelse • Aug 19
FDA Cleared EluPro Launch And Capacity Expansion Will Unlock Opportunity
Despite a substantial increase in consensus revenue growth forecasts and a sharply lower future P/E, Elutia’s consensus analyst price target has been reduced from $7.50 to $6.50. What's in the News Elutia published a study showing its antibiotic-eluting CIED biologic envelope, EluPro, controls inflammation, supports vascularization, and promotes higher growth factor release, potentially reducing scarring and infection risks in implantable cardiac device patients.Analysartikel • Jun 18
Revenues Working Against Elutia Inc.'s (NASDAQ:ELUT) Share Price
With a price-to-sales (or "P/S") ratio of 3.1x Elutia Inc. ( NASDAQ:ELUT ) may be sending very bullish signals at the...
Ny berättelse • Apr 06
FDA Cleared EluPro Launch And Capacity Expansion Will Unlock Opportunity
EluPro's FDA clearance and market entry against Medtronic's TYRX could drive significant revenue growth in the antibiotic-eluting envelope space.Analysartikel • Jan 04
Elutia Inc. (NASDAQ:ELUT) Not Doing Enough For Some Investors As Its Shares Slump 27%
Elutia Inc. ( NASDAQ:ELUT ) shares have had a horrible month, losing 27% after a relatively good period beforehand...Analysartikel • Nov 20
Elutia Inc. (NASDAQ:ELUT) Held Back By Insufficient Growth Even After Shares Climb 26%
Elutia Inc. ( NASDAQ:ELUT ) shareholders would be excited to see that the share price has had a great month, posting a...Analysartikel • Jun 28
Elutia Inc.'s (NASDAQ:ELUT) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Elutia Inc. ( NASDAQ:ELUT ) shares have continued their recent momentum with a 28% gain in the last month alone...Analysartikel • Mar 10
News Flash: 2 Analysts Think Elutia Inc. (NASDAQ:ELUT) Earnings Are Under Threat
One thing we could say about the analysts on Elutia Inc. ( NASDAQ:ELUT ) - they aren't optimistic, having just made a...Analysartikel • Feb 21
Elutia Inc.'s (NASDAQ:ELUT) Share Price Is Matching Sentiment Around Its Revenues
You may think that with a price-to-sales (or "P/S") ratio of 1.5x Elutia Inc. ( NASDAQ:ELUT ) is definitely a stock...Prognoser för vinst- och omsättningstillväxt
| Datum | Intäkter | Intäkter | Fritt kassaflöde | Kassaflöde från rörelsen | Genomsnittligt Antal analytiker |
|---|---|---|---|---|---|
| 12/31/2027 | 13 | -22 | N/A | N/A | 1 |
| 12/31/2026 | 12 | -26 | N/A | N/A | 1 |
| 3/31/2026 | 12 | -22 | N/A | N/A | N/A |
| 12/31/2025 | 12 | -16 | -47 | -45 | N/A |
| 9/30/2025 | 22 | -25 | -33 | -32 | N/A |
| 6/30/2025 | 22 | -22 | -34 | -33 | N/A |
| 3/31/2025 | 24 | -40 | -30 | -29 | N/A |
| 12/31/2024 | 14 | -45 | -23 | -23 | N/A |
| 9/30/2024 | 18 | -53 | -20 | -19 | N/A |
| 6/30/2024 | 20 | -65 | -21 | -21 | N/A |
| 3/31/2024 | 25 | -49 | -19 | -19 | N/A |
| 12/31/2023 | 25 | -41 | -22 | -22 | N/A |
| 9/30/2023 | 25 | -32 | -18 | -18 | N/A |
| 6/30/2023 | 25 | -35 | -19 | -18 | N/A |
| 3/31/2023 | 19 | -38 | -20 | -19 | N/A |
| 12/31/2022 | 24 | -36 | -22 | -21 | N/A |
| 9/30/2022 | 28 | -39 | -23 | -23 | N/A |
| 6/30/2022 | 34 | -37 | -21 | -20 | N/A |
| 3/31/2022 | 46 | -28 | -18 | -18 | N/A |
| 12/31/2021 | 47 | -25 | -16 | -15 | N/A |
| 9/30/2021 | 49 | -21 | -15 | -14 | N/A |
| 6/30/2021 | 49 | -23 | -13 | -13 | N/A |
| 3/31/2021 | 46 | -26 | -16 | -16 | N/A |
| 12/31/2020 | 43 | -25 | -14 | -14 | N/A |
| 9/30/2020 | 42 | -23 | -12 | -11 | N/A |
| 6/30/2020 | 42 | -16 | -12 | -12 | N/A |
| 3/31/2020 | 43 | -13 | -10 | -9 | N/A |
| 12/31/2019 | 43 | -12 | N/A | -7 | N/A |
| 12/31/2018 | 39 | -12 | N/A | -5 | N/A |
Analytiker Framtid Tillväxt Prognoser
Intäkter kontra sparande: ELUT förväntas förbli olönsam under de kommande 3 åren.
Resultat vs marknad: ELUT förväntas förbli olönsam under de kommande 3 åren.
Höga tillväxtresultat: ELUT förväntas förbli olönsam under de kommande 3 åren.
Intäkt vs marknad: ELUT s intäkter ( 3.2% per år) förväntas växa långsammare än marknaden för US ( 11.6% per år).
Hög tillväxtintäkter: ELUT s intäkter ( 3.2% per år) förväntas växa långsammare än 20% per år.
Tillväxtprognoser för vinst per aktie
Framtida avkastning på eget kapital
Framtida ROE: Otillräcklig data för att avgöra om ELUT s avkastning på eget kapital förväntas bli hög om tre år
Upptäck tillväxtföretag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/20 12:42 |
| Aktiekurs vid dagens slut | 2026/05/20 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Elutia Inc. bevakas av 6 analytiker. 1 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Brandon Folkes | Cantor Fitzgerald & Co. |
| Ross Osborn | Cantor Fitzgerald & Co. |
| Frank Takkinen | Lake Street Capital Markets, LLC |